Similar articles

• The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.

  Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC. Richardson PG, et al. Eur J Haematol. 2012 Jan;88(1):1-7. doi: 10.1111/j.1600-0609.2011.01721.x. Epub 2011 Nov 22. Eur J Haematol. 2012. PMID: 21991938 Free PMC article. Review.
• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

  Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. Morgan GJ, et al. Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3. Lancet. 2010. PMID: 21131037 Free PMC article. Clinical Trial.
• The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.

  Berenson JR. Berenson JR. Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):2-4. doi: 10.1016/j.clml.2011.03.025. Epub 2011 May 4. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22130220 No abstract available.
• Safety and efficacy of zoledronic acid in multiple myeloma.

  Tanimoto T, Matayoshi T, Yagasaki F, Takeuchi K, Kami M. Tanimoto T, et al. Lancet. 2011 Jun 25;377(9784):2178. doi: 10.1016/S0140-6736(11)60959-8. Lancet. 2011. PMID: 21704866 Clinical Trial. No abstract available.
• Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?

  Morgan GJ. Morgan GJ. Crit Rev Oncol Hematol. 2011 Feb;77 Suppl 1:S24-30. doi: 10.1016/S1040-8428(11)70005-1. Crit Rev Oncol Hematol. 2011. PMID: 21353177 Review.